Cargando…

Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum

Detalles Bibliográficos
Autores principales:	Louapre, C., Maillart, E., Roux, T., Pourcher, V., Bussone, G., Lubetzki, C., Papeix, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184008/ https://www.ncbi.nlm.nih.gov/pubmed/32362357 http://dx.doi.org/10.1016/j.neurol.2020.04.009

Ejemplares similares

Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
por: Maillart, Elisabeth, et al.
Publicado: (2020)

COVID-19 infection in NMO/SD patients: a French survey
por: Zeidan, Sinéad, et al.
Publicado: (2020)

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
por: Roux, Thomas, et al.
Publicado: (2017)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

CO7.1 - Anti-CD20 et sévérité de la COVID-19 chez les patients vivants avec une sclérose en plaques dans la cohorte COVISEP: un impact différent selon la forme progressive ou récurrente-rémittente de la sclérose en plaques
por: Januel, E., et al.
Publicado: (2023)

Anti-CD20 et sévérité de la COVID-19 chez les patients SEP : un impact différent chez les SEP rémittents et progressifs, dans la cohorte COVISEP
por: Januel, Édouard, et al.
Publicado: (2023)

Multiple sclerosis in 2020: un bon cru
por: Maillart, Elisabeth, et al.
Publicado: (2021)

Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study
por: Papeix, Caroline, et al.
Publicado: (2015)

Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis
por: Bayen, E., et al.
Publicado: (2015)

Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination
por: Jeantin, Lina, et al.
Publicado: (2022)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
por: Novi, Giovanni, et al.
Publicado: (2020)

COVID-19 in rheumatic disease patients on immunosuppressive agents
por: Sharmeen, Saika, et al.
Publicado: (2020)

Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis
por: Bodini, Benedetta, et al.
Publicado: (2016)

Enterocolic Lymphocytic Phlebitis Treated Preoperatively with Biologics and Immunosuppressive Agents
por: Okano, Soh, et al.
Publicado: (2022)

Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis
por: Sterlin, Delphine, et al.
Publicado: (2021)

Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic
por: Ganjei, Zakiye, et al.
Publicado: (2021)

Pharmacological immunosuppressive agents.
por: Salaman, J. R.
Publicado: (1981)

COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report
por: Sessa, Anna, et al.
Publicado: (2020)

A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica
por: Giovannelli, Jonathan, et al.
Publicado: (2021)

COVID-19 in children treated with immunosuppressive medication for kidney diseases
por: Marlais, Matko, et al.
Publicado: (2021)

Vaccination contre le SARS-CoV-2 avant l’introduction d’un traitement par anti-CD20 chez les patients atteints de sclérose en plaques : une protection durable ?
por: Jeantin, Lina, et al.
Publicado: (2023)

Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
por: Poullet, Zélia, et al.
Publicado: (2022)

Global LC/MS Metabolomics Profiling of Calcium Stressed and Immunosuppressant Drug Treated Saccharomyces cerevisiae
por: Jenkins, Stefan, et al.
Publicado: (2013)

Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study
por: Demuth, Stanislas, et al.
Publicado: (2022)

Cardiovascular effects of immunosuppression agents
por: Elezaby, Aly, et al.
Publicado: (2022)

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
por: Fan, Moli, et al.
Publicado: (2020)

PROLONGED COVID-19 INFECTION IN AN IMMUNOSUPPRESSED PATIENT TREATED WITH CASIRIVIMAB/IMDEVIMAB
por: TOOR, SUBHAN A, et al.
Publicado: (2022)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19
por: Martens-Lobenhoffer, Jens, et al.
Publicado: (2022)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

Giant cell myocarditis following COVID‐19 successfully treated by immunosuppressive therapy
por: Amiri, Afsaneh, et al.
Publicado: (2022)

Antineoplastic and Immunosuppressive Agents—Part 1
por: Lajtha, L. G.
Publicado: (1975)

Potential of immunosuppressive agents in cerebral ischaemia
por: Gupta, Yogendra Kumar, et al.
Publicado: (2011)

New immunosuppressive agents in pediatric transplantation
por: Nguyen, Christina, et al.
Publicado: (2014)

Nonimmunologic targets of immunosuppressive agents in podocytes
por: Yoo, Tae-Hyun, et al.
Publicado: (2015)

A new approach for the determination of immunosuppressive drugs using HPLC-MS/MS and Cs(+) adducts
por: Kaiser, Patricia, et al.
Publicado: (2006)

The Pharmacokinetics in Mice and Cell Uptake of Thymus Immunosuppressive Pentapeptide Using LC-MS/MS Analysis
por: Chen, Shang, et al.
Publicado: (2022)

Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy
por: Seki, Masafumi, et al.
Publicado: (2022)

The Impact of COVID-19 on Individuals Across the Spectrum of Visual Impairment
por: Shalaby, Wesam S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0oq3vegoot6m987dqqndpf53ia